The first Respiratory Syncytial Virus(RSV) vaccine Arexvy is now available in Australia.

Arexvy (recombinant respiratory syncytial virus pre-fusion F protein) was approved for the following therapeutic use:

Arexvy is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV). 

The use of this vaccine should be in accordance with official recommendations.

 

AREXVY will be available from Melbourne and Perth warehouses from the 28th of February.